Vadim Koshkin, MD

Dr. Vadim Koshkin is a genitourinary medical oncologist at the University of California San Francisco where he leads the bladder cancer clinical program in medical oncology. He completed his medical degree at the University of Chicago Pritzker School of Medicine, internal medicine training at the University of Michigan and fellowship in medical oncology at the Cleveland Clinic, and his interests are focused in clinical and translational research of bladder and prostate cancer.

Articles by Vadim Koshkin, MD

Christopher Wallis, MD, PhD, FRCSCProstate Cancer | June 24, 2025
The panel concludes with a candid discussion about the most urgent changes that could improve cancer care today.
View More
Christopher Wallis, MD, PhD, FRCSCProstate Cancer | June 24, 2025
The panel explores the importance of introducing palliative care discussions earlier in the treatment journey.
Christopher Wallis, MD, PhD, FRCSCProstate Cancer | June 24, 2025
The panel explores the overlooked burden of financial toxicity and proactively raising the topic with patients.
Christopher Wallis, MD, PhD, FRCSCProstate Cancer | June 24, 2025
The panel explores how clinicians can build trust with patients from diverse backgrounds and ensure care is patient-centered.
Christopher Wallis, MD, PhD, FRCSCProstate Cancer | June 24, 2025
The panel explores how clinicians can introduce clinical trial options while maintaining trust in the face of uncertainty.
Christopher Wallis, MD, PhD, FRCSCProstate Cancer | June 24, 2025
The panel explores the emotional weight of a cancer diagnosis and the importance of empathetic communication.
Vadim Koshkin, MDAdvanced Urothelial Carcinoma | April 15, 2025
Drs. Koshkin and Nizam discuss how a longer treatment-free interval may predict benefit from pembrolizumab rechallenge.
Vadim Koshkin, MDAdvanced Urothelial Carcinoma | April 15, 2025
Drs. Koshkin and Nizam break down recent research on pembro in patients with la/mUC who responded to first-course pembro.
Vadim Koshkin, MDUrothelial Carcinoma Diagnostics | April 7, 2025
Dr. Koshkin highlights emerging data on Nectin-4–targeted imaging and radiopharmaceuticals in urothelial cancer.
Vadim Koshkin, MDUrothelial Carcinoma Diagnostics | April 7, 2025
Dr. Koshkin shares an overview of FAP-targeted theranostics, including UCSF-led studies showing FAP PET imaging’s ability.
Tanya Dorff, MDmHSPC | February 27, 2025
The panel highlights the limitations of conventional imaging in detecting disease progression at undetectable PSA levels.
Tanya Dorff, MDmHSPC | February 26, 2025
The panel zooms in on the use of radium, enzalutamide, and other therapeutic agents, touching on patient preference trials.
Tanya Dorff, MDmHSPC | February 26, 2025
The panel focuses on decision-making between AR antagonists and abiraterone, weighing factors such as reimbursement.
Tanya Dorff, MDmHSPC | February 26, 2025
The panel goes in-depth on the use of testing and SBRT as metastasis-directed therapy in newly diagnosed prostate cancer.
Tanya Dorff, MDmHSPC | February 26, 2025
The panel explores the the role of imaging, genomics, and patient factors in the management of mHSPC.
Karine Tawagi, MDMuscle Invasive Urothelial Carcinoma | October 19, 2024
In the final part of this roundtable, Drs. Koshkin and Grivas discuss the use of EV/pembro and which patients are eligible.
Karine Tawagi, MDMuscle Invasive Urothelial Carcinoma | October 18, 2024
In part five of this roundtable, the panelists explore the use of ctDNA in the TOMBOLA and IMvigor011 trials.
Karine Tawagi, MDMuscle Invasive Urothelial Carcinoma | October 18, 2024
In the fourth part of this roundtable series, the panelists discuss recent updates on bladder-sparing treatments.
Karine Tawagi, MDMuscle Invasive Urothelial Carcinoma | October 15, 2024
In part 3 of this roundtable, the NIAGARA trial is discussed, along with cisplatin regimens and the potential of durvalumab.
Karine Tawagi, MDMuscle Invasive Urothelial Carcinoma | October 15, 2024
In the second part of this roundtable, new trials including VOLGA and EV-304 are analyzed.